cliexa announced that its cliexaAI Opioid Use Disorder Solution has been recognized as a qualified solution on the Mayo Clinic Platform, marking a major step forward in the company’s long-term effort to develop responsible, transparent, and clinically proven artificial intelligence for healthcare. The achievement reflects nearly eight years of focused work to build AI that aligns closely with real clinical reasoning and supports earlier, more informed decision making in patient care.
The cliexaAI Opioid Use Disorder Solution is a deployment-ready clinical decision support model designed to help healthcare providers identify patients who may be at risk of developing opioid use disorder before addiction takes hold. The solution combines machine learning trained on real world patient data with a proprietary clinical rules framework to deliver clear and interpretable risk assessments. Patients are categorized into four levels of risk ranging from minimal to high, allowing care teams to take timely and appropriate action within existing clinical workflows.
Health Technology Insights: The Guthrie Clinic Announces New Chief Digital Officer
The solution was developed through cliexa’s participation in the Mayo Clinic Platform Accelerate program, which supports the creation of digital health tools that can integrate directly into care delivery. By embedding the model into routine workflows, the platform provides clinicians with practical insights that are easy to understand and act upon, reinforcing evidence based care rather than replacing clinical judgment.
“This recognition reflects years of disciplined work to build AI that mirrors how clinicians think and make decisions,” said Mehmet Kazgan, Chief Executive Officer and Founder of cliexa. He explained that the company’s approach emphasizes medical knowledge, validation with real patient data, and responsible design principles to improve care quality, patient safety, and operational efficiency across healthcare systems.
Health Technology Insights: HealthLynked Teams Up with PBACO for Payer Integration
Mayo Clinic Platform Solutions Studio plays a key role in evaluating and supporting digital health technologies by reviewing clinical evidence, algorithm performance, and responsible AI practices. According to Steve Bethke, Vice President of Solution Developer Market at Mayo Clinic Platform, the qualification process helps providers feel confident that solutions have been carefully reviewed and are designed to support care teams while improving patient outcomes.
cliexa was among the earliest participants in the Mayo Clinic Platform Accelerate program in 2022 and has since worked on clinically validated AI solutions across several areas of care. Previous collaborations include cardiovascular health initiatives with the American College of Cardiology, peer reviewed research on pain and mental health in partnership with academic institutions, and an NIH supported project focused on behavioral health screening for adolescents and young adults. In addition to opioid use disorder, cliexaAI solutions are currently being used in clinical settings for triage, chronic kidney disease, and eating disorders, with plans to expand into additional therapeutic areas.
Health Technology Insights: CooperCompanies appoints Walter Rosebrough Jr to board
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
Source- businesswire
